You just read:

Santen Announces Initiation of Phase 3 Clinical Development Program (SPECTRUM) in the United States Evaluating Omidenepag Isopropyl (DE-117) for the Treatment of Glaucoma or Ocular Hypertension

News provided by

Santen Inc.

Oct 22, 2018, 08:33 ET